Bruker family reunion

STORY UPDATE

BILLERCA, Mass.—December 3, 2007—Completing the closing of the family ranks, Bruker BioSciences—home to Bruker Daltonics, Bruker AXS and Bruker Optics—announced it would acquire NMR specialist Bruker BioSpin for $914 million in cash and stock. The transaction is subject to shareholder approval, as well as various regulatory approvals and financing, but is expected to close in early 2008. "While both Bruker BioSciences and Bruker BioSpin are well established and successful companies on their own, the combined company will considerably increase and diversify its market presence, technology base, product lines, global distribution and customer support capabilities," said BioSciences Lead Director Bill Linton.

BILLERCA, Mass.—Bruker BioSciences—home to Bruker Daltonics and Bruker AXS—announced it has entered into a definitive agreement to acquire all the stock of molecular spectroscopy specialist Bruker Optics. The deal will see the exchange of $135 million in cash and stock. According to Frank Laukien, president and CEO of Bruker BioSciences, the deal will allow his company to expand its target market by approximately $700 million. The deal also sees a closer association of the Laukien family, which held a majority ownership position in both companies.

"The combined company will benefit from a more diversified industrial customer base in the pharma/biotech, diagnostic, food & beverage, semiconductor, advanced materials and raw materials industries, as well as among academic, medical school, homeland security and governmental customers," said Dan Klevisha, vice president of Bruker Optics. "We believe that we can leverage sales and marketing synergies from the resulting three Bruker BioSciences operating companies for incremental growth in several industrial applications."